Motexafin

Motexafin is a selective serotonin reuptake inhibitor (SSRI) antidepressant medication used to treat major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). It is available in tablet form and is typically taken orally once daily. The medication works by increasing the levels of serotonin, a neurotransmitter, in the brain, which helps to improve mood and reduce symptoms of anxiety and depression.

Motexafin was approved by the U.S. Food and Drug Administration (FDA) in 2019 for the treatment of major depressive disorder and OCD. It is marketed under the brand name Zelnorm. The typical starting dose for depression is 10 mg once daily, with the dose adjusted as needed based on the individual's response to treatment. For OCD, the typical starting dose is 20 mg once daily.

Common side effects of motexafin include nausea, dizziness, drowsiness, and sexual dysfunction. Serious side effects may include suicidal thoughts or behaviors, serotonin syndrome, and an increased risk of bleeding. It is important to consult a healthcare provider before starting motexafin, as it may not be suitable for individuals with certain medical conditions or those who are taking other medications.

Motexafin should be taken exactly as prescribed by a healthcare provider. It is important to follow the dosage instructions and not to suddenly stop taking the medication without consulting a doctor. If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next dose, in which case the missed dose should be skipped.